Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis
Treatment with AD + RHT showed improved PFS and better treatment tolerability compared to AI + RHT. Our results support the use of AD instead of AI for the treatment of patients with LMS in combination with RHT.
Authors
- Hans Roland Dürr (ORCID: https://orcid.org/0000-0002-1347-1173)
- Michael von Bergwelt‐Baildon (ORCID: https://orcid.org/0000-0002-1952-052X)
- Emanuel Stutz (ORCID: https://orcid.org/0000-0002-5837-2048)
- Anton Burkhard‐Meier (ORCID: https://orcid.org/0009-0002-9801-3530)
- Luc M. Berclaz (ORCID: https://orcid.org/0000-0003-4405-138X)
- Alexander Klein (ORCID: https://orcid.org/0000-0002-5562-9872)
- Dorit Di Gioia
- Vindi Jurinović
- Wolfgang G. Kunz (ORCID: https://orcid.org/0000-0002-5021-1952)
- Thomas Knösel (ORCID: https://orcid.org/0000-0002-1822-0197)
- Markus Albertsmeier (ORCID: https://orcid.org/0000-0002-5028-5062)
- Nina‐Sophie Schmidt‐Hegemann
- Lars H. Lindner (ORCID: https://orcid.org/0000-0003-3708-8264)
- S. Abdel-Rahman (ORCID: https://orcid.org/0000-0003-3674-3183)
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
- LMU Klinikum (DE)
- Zimmer Biomet (Germany) (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70655
- Citations
- 3
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56